<!DOCTYPE html>

<html class="no-js">
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <title></title>
    <meta name="description" content="" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />

  </head>
  <body>
    <!-- main div group -->
    <div style="font-family: Arial;">

    <div style=" font-size: 20px;"><b> Treating patients: A Challenge, or Not?</b></div>
    <br>
    <div>Sponsored by Somemed Inc.</div>
    <br>
    
    <div style="font-size: 18px;background: #e0e0e0;"> <b>Significant challenges exist when managing PHN in the elderly</b><sup>1</sup>
    </div>

    <br>
  <div><u><b>Treatment considerations</b></u><sup>1</sup></div>

  <div> 
      <ul>
  <li>
    The patient is typically a human
  </li>
  <li>
  Elderly patients frequently have multiple comorbidities, take
  multiple medications, and are particularly sensitive to drug side
  effects
</li>
<li>
In elderly patients with impaired physical function, drugs that cause
  dizziness, drowsiness, or somnolence may increase the risk of
  falls
</li>
</ul>
</div>

<div style="font-size: 18px;background: #e0e0e0;"> <b> LOREM<sup>&reg;</sup> (loremin) can help with the challenge of brain management in the humans</b><sup>2</sup></div>

<br>

<div><b>Indication and Usage</b></div>

<br>

<div >
    LOREM<sup>&reg;</sup> (loremin) tablets are indicated for the management of
    human brain activities. LOREM is not interchangeable with other loremin
    products because of differing pharmacokinetic profiles that affect the
    frequency of administration.</div>

    <br>

<div>For more information about LOREM, please see
  the full</span>
  <a href="http://www.nytimes.com/2014/11/18/science/monarchs-may-be-loved-to-death.html?ref=science">Prescribing Information</a>
  
  and
  
  <a href="http://artsbeat.blogs.nytimes.com/2014/11/23/homeland-recap-was-saul-heroic-or-something-else/?ref=arts">
    Medication Guide</a>.
</div>
<br>

<img 
style="display:block; margin-left: auto;margin-right: auto;"   width="25%"
      src="../images/Exercise1-code-challenge-image.png"
      alt="image"/>
    
      

<br>
<br>


<small>

 <b>References:</b>
 
<br>
            <b>1.</b> Gupta A, Li S. Safety and efficacy of once-daily gastroretentive
            loreminar in patients with postherpetic neuralgia aged 75 years and over.
            <em>Drugs Aging</em>.
            <br> 2013;30:999-1008.

 <br>
            <b>2.</b> Harden RN, Kaye AD, Kintanar T, Argoff CE. Evidence-based guidance
            for the management of postherpetic neuralgia in primary care.
            <em>Postgrad Med</em>. 
            <br>
            2013;125:191-202.
<br>
<br>
    
<div >&copy; November 2017, Somemed Inc. &nbsp;&nbsp;&nbsp; All rights reserved. &nbsp;&nbsp;&nbsp;
    HAH-0001</div>


</small>


</div>

  </body>
</html>
